The downgrade from Buy to Hold suggests that Truist Securities sees limited upside potential or increased risk in Axonics' stock. The reduction in the price target further implies a tempered expectation for the stock's performance. This could lead to a negative sentiment among investors and potentially result in a short-term decline in the stock price.